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2 Fred Hutchinson Cancer Research Center, Seattle, WashingtonIn previous years, the American Society for Blood and
Marrow Transplantation (ASBMT) organized a comprehen-
sive Education Supplement published in Biology of Blood and
Marrow Transplantation in conjunction with the Tandem
meeting. At the recommendation of the ASBMT Board of
Directors, the Education Supplement for this year was
condensed and will now comprise critical reviews of 3 topics
selected from among those presented at the 2014 BMT Tan-
dem Meetings. The modiﬁcation of the Education Supple-
ment will reduce meeting costs and focus speciﬁcally on
areas of continued debate or rapid evolution. The 3 selected
subjects include the role of hematopoietic cell trans-
plantation (HCT) for treatment of amyloidosis and chronic
lymphocytic leukemia (CLL) and the use of maintenance
therapy to eliminate minimal residual disease after HCT. The
3 reviewswill also be published consecutively in the January,
February, and March issues of the journal.
In the ﬁrst review, Dr. Steven Devine re-examines the role
of high-dose chemotherapy in the treatment of light-chain
amyloidosis, an extremely controversial topic. Some groups
have shown impressive survival results for patients who
received high-dose chemotherapy with autologous HCT, but
the only randomized trial to address this question showed no
improvement in survival for patients treated with autolo-
gous HCT as compared with those who received a non-
transplant treatment. The randomized study has been
criticized because some deaths in the transplant arm could
have reﬂected a lack of experience in providing the skilled
ancillary support and prophylaxis measures required for
patients with amyloidosis during the mobilization and
apheresis of hematopoietic cells and the conditioning
regimen at some centers. Retrospective studies showing
favorable results for transplantation cannot adequately ac-
count for selection factors and lead-time bias in comparison
with conventional treatment.
In the second review, Drs. Christopher Hourigan, Philip
McCarthy, and Marcos DeLima discuss the evolving role ofFinancial disclosure: See Acknowledgments on page S1.
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HCT. The past decade has seen remarkable advances in the
ability to detect minimal residual diseasewith the use of ﬂow
cytometry and molecular methods. Recent studies have
shown that the presence of minimal residual disease before
transplantation and early afterward portends a high risk of
subsequent clinical recurrence. At the same time, novel
agents that have limited effects on graft function have
become available for testing to prevent clinical recurrence,
after either autologous or allogeneic HCT. These de-
velopments offer new opportunities for reducing the risk of
clinical recurrence, one of the most devastating and frequent
reasons for failure after HCT.
In the third review, Dr. Marcie Tomblyn reviews cellular
therapies for CLL using either autologous or allogeneic HCT.
Standards for treatment of this disease are rapidly changing
as new agents targeting signal transduction pathways in CLL
cells become available. Previous studies have not demon-
strated a survival beneﬁt for autologous transplantation in
patients with CLL, but for certain subsets of patients, allo-
geneic transplantation can provide such beneﬁt. Dr. Tomblyn
also discusses novel cellular therapies currently in develop-
ment to decrease the risk of recurrence after transplantation
for treatment of CLL.
Taken together, these 3 reviews provide an overview of
some important questions in HCT.We owe a debt of gratitude
to the authors for their hard work and dedication in pre-
paring these reviews for the beneﬁt of the transplant com-
munity. On behalf of the ASBMTand the Center for Blood and
Marrow Transplant Research, we thank the authors for going
the extra mile to provide their thoughtful and insightful
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